Actimed’s Strategic Power Play for the Future of Muscle Health

LONDON, UK – August 06, 2026

In a decisive maneuver that signals a doubling down on its core strategy, UK-based Actimed Therapeutics announced today it has reacquired full global rights to S-oxprenolol, a promising drug candidate for muscle wasting disorders. While corporate press releases about licensing agreements are common, this move is anything but routine. By reclaiming the asset from Faraday Pharmaceuticals, Actimed isn't just shuffling its pipeline; it's consolidating power, sharpening its focus, and making a bold statement about its ambition to lead the high-stakes, high-need market for muscle health.

The transaction reverses a 2021 deal where Actimed licensed rights to Faraday to develop S-oxprenolol for indications outside of Amyotrophic Lateral Sclerosis (ALS), a move intended to bring in capital to advance Actimed’s other assets. Now, with full control restored, the company has unified its strategy around a single, powerful vision: tackling the devastating impact of muscle loss across a spectrum of diseases, from rare neurological conditions to the side effects of modern weight-loss treatments.

The Strategic Chess Move: Why Full Control Matters

To understand the significance of today’s announcement, one must look at the context. The original 2021 licensing agreement was a pragmatic decision for a clinical-stage company, providing non-dilutive funding and allowing a partner to explore the drug’s potential in broader areas like cancer cachexia. Actimed wisely retained the rights for ALS, recognizing the compound's unique potential in that specific, devastating disease.

However, the landscape has shifted. With Faraday Pharmaceuticals' changing operational status creating an opportunity, Actimed moved decisively to bring S-oxprenolol back into the fold. This wasn't merely an opportunistic buyback; it was a strategic imperative. The company now holds all the cards for S-oxprenolol's future, from manufacturing and clinical development to commercialization, across all possible indications.

As Actimed CEO Robin Bhattacherjee stated, the transaction “enhances our strategic flexibility and opportunities around this asset.” This is corporate language for a profound shift. Actimed is no longer just the developer of S-oxprenolol for ALS; it is the sole custodian of a potential platform drug. This allows for a cohesive development plan, eliminating the complexities of partnered programs and ensuring that every discovery and every clinical success directly builds the company's value. For investors and potential partners, Actimed now presents a much clearer, more potent investment thesis centered on its mastery of a specific, crucial area of medicine: anabolic-catabolic transforming agents (ACTAs).

A Renewed Hope in the Fight Against ALS

The most immediate and profound impact of this strategic consolidation is the renewed momentum for S-oxprenolol as a potential treatment for Amyotrophic Lateral Sclerosis (ALS). A cruel and relentless neurodegenerative disease, ALS progressively destroys motor neurons, leading to muscle atrophy, paralysis, and ultimately, death. For many patients, the direct cause of mortality and the devastating decline in quality of life stems from the wasting of respiratory and skeletal muscles.

The current treatment landscape offers limited hope. Drugs like Riluzole provide only a modest survival benefit of a few months, and the recent voluntary withdrawal of Relyvrio from the market after a failed Phase 3 trial was a gut-wrenching setback for the community. There is a desperate, urgent need for therapies that can do more than just slightly slow the decline.

This is where S-oxprenolol enters the picture. Its preclinical data is compelling. In animal models of ALS, the drug demonstrated what Actimed’s Chief Medical Officer, Dr. Fabio Dorigotti, calls a “multi-modal pharmacology.” It not only preserved muscle mass but also had a significant effect on survival. In one key study, ALS mice treated with S-oxprenolol survived 33% longer than those on a placebo. Perhaps more impressively, these animal models suggested it could be more effective than the long-standing standard of care, Riluzole. This focus on directly combating the muscle wasting that is so central to the patient experience in ALS is a novel and highly promising approach.

The drug’s potential has already been recognized by regulators, having received Orphan Drug Designation from the U.S. FDA. This status provides significant incentives and a potentially smoother regulatory path, acknowledging the high unmet need in this patient population. By regaining full control, Actimed can now drive the ALS program forward with singular focus.

Beyond a Single Disease: A Pipeline Built on Muscle

While the ALS indication is the clear priority for S-oxprenolol, looking at Actimed’s broader pipeline reveals a much larger and more ambitious strategy. S-oxprenolol does not exist in a vacuum; it sits alongside S-pindolol, another ACTA with promising Phase 2a data in treating cancer cachexia—a severe muscle-wasting syndrome that can be more lethal than the cancer itself.

More intriguingly, Actimed is exploring S-pindolol's potential to address one of the most significant unintended consequences of the 21st century's biggest pharma trend: muscle loss associated with GLP-1 agonists. The blockbuster success of drugs like Ozempic and Wegovy in promoting weight loss has been revolutionary. However, a growing body of evidence shows that a significant portion of the weight lost is not fat, but lean muscle mass. This is a critical issue, particularly for older adults, as it can compromise metabolic health and physical function.

Herein lies the brilliance of Actimed's strategy. The company is positioning itself not just as a developer of drugs for rare diseases, but as a provider of essential solutions for muscle health in massive, mainstream markets. The same biological principles that allow its drugs to fight muscle wasting in cancer or ALS could be harnessed to ensure healthier, more sustainable weight loss for millions. By developing S-oxprenolol for the ultra-orphan ALS market and S-pindolol for cachexia and the GLP-1 space, Actimed is pursuing a balanced portfolio that spans high-need niche indications and massive market opportunities.

The Road Ahead: From Lab Bench to Patient Bedside

With the strategic realignment complete, the hard work now begins. Actimed’s immediate focus is on completing the Chemistry, Manufacturing, and Controls (CMC) work for S-oxprenolol. This is the foundational, unglamorous but absolutely critical step of ensuring a drug can be produced safely, consistently, and at scale. It is the gateway to initiating human clinical trials.

Navigating the path to approval for an ALS drug is notoriously difficult. The disease's complexity and the challenges of clinical trial design have led to many high-profile failures. By taking on full responsibility for S-oxprenolol, Actimed is also shouldering the full financial and scientific risk of this journey. Yet, it also stands to reap the full reward—both for its shareholders and for the patients it seeks to serve.

Today's announcement is a clear signal that Actimed is ready to take that risk. The company has consolidated its assets, clarified its mission, and aligned its entire strategy around a singular, vital goal. For patients with ALS and other muscle-wasting conditions, this focused commitment is a welcome development. For the rest of the industry, all eyes will be on Actimed as it embarks on the next crucial phase, attempting to transform a promising molecule into a life-changing medicine.